Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Pulmonary and diaphragmatic pathology in collagen type I α1 mutant mice with osteogenesis imperfecta

  • Carolyn J Baglole
  • , Feng Liang
  • , Hussein Traboulsi
  • , Angela Rico de Souza
  • , Christian Giordano
  • , Josephine T Tauer
  • , Frank Rauch
  • , Basil J Petrof

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Abstract

BackgroundOsteogenesis imperfecta (OI) is most often caused by mutations in type I collagen genes. Respiratory complications have been largely attributed to spine and ribcage deformities. We hypothesized that direct involvement of the pulmonary parenchyma and/or diaphragm by the disease may occur.MethodsIn Col1a1Jrt/+ mice, a model of severe dominant OI, mean linear intercept length (Lm) was used to assess the distal airspace size. Cross-sectional area (CSA) and myosin heavy chain (MyHC) phenotype of the diaphragm muscle fibers, as well as contractile properties, were determined. OI mice were also treated with neutralizing antibodies against transforming growth factor-β (TGF-β).ResultsDistal airspace enlargement occurred in OI mice (Lm +27%). Diaphragmatic thickness and fiber number were reduced, with increases in fast-twitch type IIx/IIb MyHC fibers. Ex vivo force generation (normalized for CSA) of the diaphragm was also significantly reduced. The increased Lm values found in OI mice were not prevented by anti-TGF-β antibody treatment.ConclusionsThe Col1a1Jrt/+ mouse model of OI demonstrates: (1) pulmonary airspace enlargement not driven by TGF-β; and (2) reduced muscle mass and intrinsic contractile weakness of the diaphragm. These results suggest a complex and multifaceted basis for respiratory complications in OI that cannot be solely attributed to bone manifestations.

OriginalspracheEnglisch
Seiten (von - bis)1165-1171
Seitenumfang7
FachzeitschriftPediatric research
Volume83
Ausgabenummer6
DOIs
PublikationsstatusVeröffentlicht - Juni 2018
Extern publiziertJa

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gute Gesundheit und Wohlergehen
    SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

  • 302 Klinische Medizin

Dieses zitieren